Abstract 151P
Background
Depth of response (DpR) and early tumor shrinkage (ETS) are established predictors of overall survival (OS) in colorectal and gastric cancer; however, data for pancreatic cancer (PC) are limited.
Methods
This study was conducted as part of two multicenter retrospective studies (NAPOLEON and NAPOLEON-2) of patients (pts) with measurable advanced PC tumors. Cohort 1 included 292 pts treated with gemcitabine/nab-PTX (GnP, 184 pts) and FOLFIRINOX (FFX, 108 pts) as first-line chemotherapy, and Cohort 2 included 88 pts treated with nanoliposomal irinotecan, fluorouracil and folinic acid as second-line chemotherapy. DpR was defined as the maximum tumor shrinkage percentage on imaging compared with the pre-treatment level. Pts were divided by DpR into three groups: control (Group A), responder (Group B), and deep responder (Group C). ETS was defined as ≥20% reduction from the start of treatment to the second evaluation.
Results
In Cohort 1, DpR was −2.3 to +1550% in Group A, −28.6 to −2.5% in Group B, and −100.0 to −28.6% in Group C. The baseline C-reactive protein/albumin ratio differed significantly by group (p=0.04). The median OS (mOS) was significantly longer in Group C (17.2 months) and Group B (11.5 months) than in Group A (8.4 months), (hazard ratio [HR], 95% confidence interval [CI]: 0.30, 0.22–0.42, p<0.01; and 0.58, 0.43–0.79, p<0.01, respectively). The mOS was also significantly longer in the ETS group overall (HR 0.46, 95% CI 0.35–0.61, p<0.01) and in both the GnP and FFX subgroups. In Cohort 2, DpR was +18.4 to +128.6% in Group A, −2.9 to +17.9% in Group B, and −80.0 to −3.2% in Group C. The baseline prevalence of ascites differed significantly by group (p=0.04). The mOS was significantly longer in Group C (10.9 months) than in Group A (4.6 months; HR 0.33, 95% CI 0.17–0.65, p<0.01), but mOS in Group B (6.8 months) did not differ significantly from Group A (p=0.10).
Conclusions
This is the first report that DpR and ETS might be predictors of OS in pts with PC on standard chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract